BXOS116

BXOS116 is a novel small molecule chemical drug being developed by Bioxios (Beijing) Biotechnology (拜西欧斯（北京）生物技术有限公司) for the treatment of acute ischemic stroke (AIS). It is currently in Phase 1 clinical development, with a study (CTR20261863) evaluating the safety, tolerability, immunogenicity, and pharmacokinetics of single and multiple ascending doses in healthy adult volunteers. As an injectable therapy, BXOS116 is intended for the acute management of stroke, likely targeting neuroprotective pathways or mechanisms to reduce brain injury following an ischemic event. The specific molecular target of BXOS116 has not been publicly disclosed in the available clinical trial registries.